H.C. Wainwright Sticks to Its Buy Rating for Actinium Pharmaceuticals (ATNM)
September 21 2022 - 08:55AM
TipRanks
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on
Actinium Pharmaceuticals (ATNM - Research Report) today and set a
price target of $45.00. The company's shares closed yesterday at
$7.66.According to TipRanks, Pantginis is an analyst with an
average return of -23.4% and a 22.16% success rate. Pantginis
covers the Healthcare sector, focusing on stocks such as Humanigen,
Astria Therapeutics, and Krystal Biotech.The word on The Street in
general, suggests a Strong Buy analyst consensus rating for
Actinium Pharmaceuticals with a $25.60 average price target, a
234.20% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jan 2023 to Feb 2023
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Feb 2022 to Feb 2023